Boughton Soleil has reported the sale of 3,462 shares of Hims & Hers Health, Inc. as part of a Rule 10b5-1 trading plan. This transaction, dated October 28, 2026, is significant as it reflects the ongoing management of stock ownership within the company.

The sale was executed at a price of $27.60 per share, resulting in a total transaction value of approximately $95,000. Following this sale, Boughton Soleil retains ownership of 293,886 shares of Hims & Hers Health, Inc.

Background

Boughton Soleil, identified under the Central Index Key (CIK) number 0001837817, is associated with Hims & Hers Health, Inc., a company operating in the healthcare sector. Hims & Hers Health, Inc. is classified under the SIC code for services related to the offices and clinics of doctors of medicine. The company is publicly traded, and its shares are listed under the ticker symbol HIMS.

What the Filing Says

The filing states, "The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2026 by the Reporting Person." This indicates that the transaction was planned in advance, adhering to SEC regulations to avoid insider trading concerns.

Impact

This sale may have implications for other stakeholders, including investors and analysts monitoring Hims & Hers Health, Inc. The move could signal a strategic decision by Boughton Soleil, who serves as the Chief Legal Officer of the company, to manage personal stock holdings amid changing market conditions.

What's Next

The filing does not say what happens next.